< 0.00001; ARD, 0.88%; NND, 113). Elevated risks were observed with tepotinib, savolitinib, amivantamab, and rilotumumab. Notably, monoclonal antibodies carried a higher edema risk than tyrosine kinase inhibitors, and combination therapy showed greater risk than monotherapy. The risk was also higher in lung cancer and in first-line settings. These findings provide comprehensive evidence for the risk profile of peripheral edema and support individualized monitoring in clinical practice.
Jing et al. (Sun,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: